Noteworthy Price Action: A Reversal for Aclaris Therapeutics Inc Is Not Near. The Stock Rises Again

Noteworthy Price Action: A Reversal for Aclaris Therapeutics Inc Is Not Near. The Stock Rises Again

The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) is a huge mover today! The stock increased 3.61% or $0.98 on November 23, hitting $28.14. About 245,677 shares traded hands. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 43.13% since April 22, 2016 and is uptrending. It has outperformed by 37.72% the S&P500.
The move comes after 6 months positive chart setup for the $719.14 million company. It was reported on Nov, 24 by Barchart.com. We have $29.83 PT which if reached, will make NASDAQ:ACRS worth $43.15 million more.

Analysts await Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings on March, 22. They expect $-0.67 earnings per share, down 139.29% or $0.39 from last year’s $-0.28 per share. After $-0.50 actual earnings per share reported by Aclaris Therapeutics Inc for the previous quarter, Wall Street now forecasts 34.00% negative EPS growth.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 4 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $34 is the highest target while $20 is the lowest. The $31.67 average target is 12.54% above today’s ($28.14) stock price. Aclaris Therapeutics has been the topic of 8 analyst reports since November 2, 2015 according to StockzIntelligence Inc. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Friday, August 12. The company was initiated on Friday, September 30 by JMP Securities. William Blair initiated it with “Outperform” rating and $30 target price in Monday, November 2 report. As per Monday, November 2, the company rating was initiated by Jefferies. The rating was initiated by Citigroup on Monday, November 2 with “Buy”. The rating was initiated by Guggenheim on Friday, June 10 with “Buy”. The stock has “Buy” rating given by Jefferies on Monday, September 19.

According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”

More recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Fool.com which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Also Investorplace.com published the news titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” on November 16, 2016. Globenewswire.com‘s news article titled: “Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of …” with publication date: December 16, 2015 was also an interesting one.

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment